6h ago
16.6% Weight Loss in Phase 3 Obesity Trial
SYNCHRONIZE-1 Phase III trial delivered average 16.6% weight loss after 76 weeks using the efficacy estimand – key progress for managing chronic obesity and metabolic conditions.
••
Chronic Health Brief
Created by Brenda Routt
Peer‑reviewed research and policy news for chronic disease patients and families
Digest Calendar
April 2026Sun
Mon
Tue
Wed
Thu
Fri
Sat
Recent Posts
Explore the latest content tracked by Chronic Health Brief
6h ago
Elrexfio's Phase 3 Wins Boost Myeloma Options
Pfizer's Elrexfio bispecific shows strong Phase 3 efficacy in pretreated multiple myeloma patients:
- ORR 58% among 97 patients with ≥4 prior...
6h ago
Unique Heart Disease Risk Factors for Women
Women have unique risk factors for heart disease, spotlighted in a concise 7:09 YouTube video to bridge gender gaps in CV awareness and empower prevention.
6h ago
Mass General Validates Genetic Tool Predicting Risk for 8 CV Conditions
- New PRS tool from Mass General Brigham assesses inherited risk for 8 conditions (CAD, AFib, T2D, VTE, TAA, extreme HTN, severe high cholesterol,...
6h ago
Sugar Doesn't Feed Cancer: Focus on Complete Nutrition for Treatment Energy
- Myth busted: Cancer cells use glucose, but so do your brain, muscles, and immune system—cutting sugar/carbs does NOT stop cancer growth.
- Your body...
6h ago
Personalized Vaccine Shows Early Promise Against Deadly Pancreatic Cancer
Hope for PDAC patients: A new immunotherapy vaccine, made from a patient's own tumor, triggered immune responses in 50% of 16 trial participants.
-...
6h ago
MS-553: Promising PKCβ Inhibitor for Relapsed/Refractory CLL
Emerging targeted option for hard-to-treat CLL patients:
- Selective PKCβ inhibitor MS-553 evaluated in phase 1 trial for relapsed/refractory...
6h ago
Lifelong LE8 Scores from Early Adulthood Cut CVD Risk by 73%
Life's Essential 8 (LE8) tool tracks CVH via 8 factors (BMI, cholesterol, BP, glucose, activity, diet, smoking, sleep) over 25 years in Framingham...
6h ago
CLL17 Trial: Fixed-Duration Therapies Match Continuous Ibrutinib in Frontline CLL
Key CLL17 results from ASH 2025:
- Fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib non-inferior to continuous ibrutinib for 3-year...
12h ago
Chronic Health Brief · Apr 29 Daily Digest
Diabetes & Obesity Trial Results
- 🔥 Biomea Fusion T1D Phase 2: Biomea Fusion's Phase 2 COVALENT-112 trial showed a 52% increase from baseline in...
1d ago
2026 GLP-1 Updates: Sleep Apnea, Brain Effects & Risks Beyond Weight Loss
Key non-weight impacts from Ozempic, Wegovy, Zepbound podcast:
- Sleep apnea: FDA approvals for obstructive sleep apnea
- Brain/addiction: Effects on...
1d ago
Eight Vaccines Linked to Lower Dementia Risk via Inflammation Protection
- Viral mechanism: Infections like herpes, chickenpox, COVID trigger brain inflammation, impairing cognition and raising dementia risk.
- Shingles...
1d ago
Dr. Li's Top Fruits for Diabetics: Stabilize Blood Sugar, Avoid These Risks
Dr. William Li's guide empowers diabetics with fruit choices using GI vs GL:
- Top 10 for control: Cherries #1⭐, peaches #2, guava #3, strawberries...
1d ago
CAR-T Trends: Autoimmune Remissions and KIR Innovations vs Exhaustion
CAR-T therapy surges beyond cancer:
- Autoimmune wins: 47yo with refractory AIHA, ITP, APLAS achieved rapid, durable remission after CD19 CAR-T...
1d ago
BP Meds' Lifespan Edge vs. Foods Beating Pills
Rilmenidine's anti-aging promise: BP drug extends worm/mice lifespans, mimics caloric restriction effects. Safe for hypertension outside US, but...
1d ago
Survodutide Hits Wegovy-Level Weight Loss with Muscle-Sparing Potential
- Efficacy match: 13.4-17% placebo-adjusted weight loss after 76 weeks, comparable to Wegovy (12.4-14.4%) but below Zepbound (17.8-20.1%).
- Muscle...
1d ago
Icovamenib Shows Dose-Dependent C-Peptide Preservation in Early T1D
Promising beta-cell protection in Type 1 diabetes:
- 52% C-peptide increase at Week 12 with 200 mg (n=5, diagnosed 0-3 years), dose response vs 100...
1d ago
Seniors' Morning Cardiac Peak: Risks and 5-Min Prevention Routine
Heart attacks and strokes peak in the 6-10 AM 'danger zone' due to circadian stresses.
Key vulnerabilities for seniors:
- BP/heart rate surge +...
1d ago
AACR 2026: Moderna, Marengo Combo Therapies Shine in Melanoma, Breast Cancer
Emerging combo therapies target tumors multi-modally while curbing resistance:
- Marengo's invikafusp alfa + Trodelvy: In Phase 2 for pretreated...
1d ago
Oncolytic Immunotherapy: New Hope for Melanoma Non-Responders
Exciting progress for those failing standard melanoma therapies:
- Core challenge addressed: Tackles patients unresponsive to today's powerful...